title: Pharmacology in space. Part 2. Controlling motion sickness.
abstract: In this second article in the two-part series on pharmacology in space, Claire Lathers and colleagues discuss the pharmacology of drugs used to control motion sickness in space and note that the pharmacology of the 'ideal' agent has yet to be worked out. That motion sickness may impair the pharmacological action of a drug by interfering with its absorption and distribution because of alteration of physiology is a problem unique to pharmacology in space. The authors comment on the problem of designing suitable ground-based studies to evaluate the pharmacological effect of drugs to be used in space and discuss the use of salivary samples collected during space flight to allow pharmacokinetic evaluations necessary for non-invasive clinical drug monitoring.
authors.forename: C M
authors.initials: CM
authors.lastname: Lathers
authors.forename: J B
authors.initials: JB
authors.lastname: Charles
authors.forename: M W
authors.initials: MW
authors.lastname: Bungo
mesh_terms: D006801:Humans; D009041:Motion Sickness / Q000188:drug therapy*; D013026:Space Flight